In 1Q13, the NASDAQ Biotechnology Index surpassed its all-time high set at the peak of the genomics bubble in 2000; the BioCentury 100 indices and S&P 500 also continued their gains from previous quarters. Excluding partnerships, biotech pulled in only $6 billion owing to few debt deals, although follow-ons increased to $2.3 billion. Six initial public offerings (IPOs) trickled in last quarter versus 8 deals in 1Q12, and private financing declined, down 20% from 1Q12.
The BioCentury 100 and NASDAQ Biotechnology indices were up 16–17% last quarter, whereas the Dow and S&P 500 were up 10–11%.
Excluding partnerships, biotechs raised $6 billion, below the $8.6 billion raised in 1Q12.
Six companies raised $328.5 million through IPOs in 1Q13, versus eight that raised $459.3 million a year ago.
Private biotechs raised $963.2 million in 1Q13, vs. $1.2 billion in 1Q12, and down from $1.9 billion in 4Q12.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, W. 1Q13—Stocks reach all-time high. Nat Biotechnol 31, 378 (2013). https://doi.org/10.1038/nbt.2584
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2584
